Genprex, Inc.
Close on Oct 19, 2026
- Market cap
- $974.71K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Genprex has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Genprex filed with the SEC
EX-99.1 to Form 8-K
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Listing notice · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Genprex Provides Update on Diabetes Gene Therapy Program
Material agreement · Agreement terminated · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Genprex Signs Exclusive License to Additional Diabetes Technology with the
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
GENPREX, INC. ANNOUNCES $4 MILLION
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial
Other events · EX-99.1 to Form 8-K
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of
Other events · EX-99.1 to Form 8-K
Genprex Expands Gene Therapy Oncology Pipeline
Other events · EX-99.1 to Form 8-K
Genprex Receives U.S. FDA Fast Track Designation for REQORSA ™ Immunogene Therapy
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K